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Advances in Thrombolytic Therapy for
Acute Myocardial Infarction
Eric J. Topol, MD
There has been rapid proliferation of understanding and experience with thrombolytic
therapy for acute myocardial infarction. Over the last few years, selective intracoronary
infusion of lytic therapy has been replaced by intravenous administration because of the
fundamental importance of time to reperfusion. Newer thrombolytic agents, such as
tissue plasminogen activator (t-PA) and acylated streptokinase (APSAC), with properties
distinct from streptokinase (SK) and urokinase, have been developed and have under-
gone extensive clinical trial evaluation. This review will focus primarily on the recent
advances in thrombolytic therapy, with particular attention to efficacy, safety, and com-
parative aspects of the various agents currently or soon to be available.
S ince the initial work with streptokinase (SK)
more than 40 years ago by Tillett, Sherry, and
colleagues,12 there have been prodigious advances
in the application of this form of therapy to patients.
The major clinical focus of thrombolytic therapy has
been acute myocardial infarction because of its high
incidence, relatively small burden of fresh4.(minutes
to hours) thrombus, ease of demonstrating clot dis-
solution, and fatal potential. Paralleling the develop-
ment of fibrinolytic agents, several milestones in
diagnosing and treating the patient with acute myo-
cardial infarction have promoted the current rapid
growth phase of clinical investigation. In chronolo-
gic order these include the postulate by Herrick in
1912 that coronary thrombosis was the inciting
event of myocardial infarction,3 direct infusion of SK
into the infarct-related artery by Chazov and later
Rentrop in the mid- and late 1970s,45 and the angio-
graphic demonstration of total occlusion of the coro-
nary artery in nearly 90% of patients with fewer
than 4 hours of symptoms by DeWood, with confir-
mation of thrombus at early coronary bypass sur-
gery.6 The large experience of DeWood and col-
leagues also served to demonstrate the safety of im-
mediate coronary angiography and thus permitted
the wide use of this procedure in the early hours of
evolving myocardial infarction.
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THE FULL CIRCLE: INTRAVENOUS TO
INTRACORONARY TO INTRAVENOUS
THROMBOLYTIC THERAPY
The earliest application of thrombolytic therapy for
acute myocardial infarction involved intravenously
administered streptokinase (SK).7 However, early
clinical trials that used intravenous SK or urokinase
did not show efficacy in terms of mortality reduc-
tion.89 The disparity between previous findings and
the current experience relates to the relatively late
(up to 24 hours) administration and considerably
lower doses of the fibrinolytic enzymes. Despite
these shortcomings, pooled analysis of the intrave-
nous studies of SK suggested a significant 20% re-
duction in mortality compared with placebo or con-
ventional therapy.1#{176}
Intracoronary fibrinolytic therapy became popu-
lar in the early 1980s after Rentrop, Ganz, and others
demonstrated the high efficacy of selective SK infu-
sion for reperfusion of the occluded coronary ar-
tery.1112 In a major precedent for regulatory issues,
(discussed subsequently) in 1982 the United States
Food and Drug Administration (FDA) approved the
use of intracoronary SK for acute myocardial infarc-
tion. The approval (and subsequent approval for uro-
kinase) was based on the ability of intracoronary SK
to restore patency of the occluded coronary artery
without any data available at that time on ventricu-
lar function or mortality.
Two major randomized studies of intracoronary
SK subsequently demonstrated salutary effects
beyond the demonstration of reperfusion.13’14 The
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rction. Heart Lung, 1987 (in press).
Western Washington intracoronary SK trial demon-
strated a striking 67% reduction of in-hospital mor-
tality without improvement in ventricular func-
tion.’3 This seemingly paradoxical finding probably
resulted from the relatively late time of reperfusion
in the trial, with a mean time to SK initiation of 4.6
hours from symptom onset. Other randomized stud-
ies of intracoronary SK have similarly been unable
to demonstrate improvement of ventricular function
when therapy is delayed more than 3 hours from the
symptom onset.’52#{176} In contrast, the Dutch Inter-Uni-
versity randomized trial of intracoronary SK, with
the adjunctive use of intravenous SK (43%) or coro-
nary angioplasty (17%), showed both augmentation
of ventricular function and reduction in mortal-
ity.’421 In this trial, patients received intracoronary
SK at an earlier time-3.25 hours from the onset of
symptoms. A smaller trial by Anderson et al., in
which patients were treated relatively early, also
demonstrated benefit of ventricular function.22
Despite the potential for infarct vessel recanaliza-
tion, recovery of ventricular function and mortality
sparing, intracoronary administration of SK has lost
favor. At this point, as far as a primary reperfusion
strategy, it can almost be considered defunct. The
reasons for the resurgence of interest in intravenous
lytic therapy stem from several important considera-
tions. First, intracoronary SK is quite impractical. In
1986, only a minority (19%) of U.S. hospitals were
equipped with a cardiac catheterization labora-
tory.23 Even in hospitals where cardiac catheteriza-
tion is available, a 24-hour on-call arrangement is
necessary, which is not only expensive but also
leads to inherent delays during nonworking hours. It
takes approximately 1.5 to 2 hours, on average, to
achieve infarct artery recanalization in patients
when therapy is primarily dependent on obtaining
direct coronary access. Second, for intracoronary
streptokinase to be effective, a systemic lytic state is
a prerequisite.24’25 Thus, the lower doses generally
chosen for intracoronary compared with intrave-
nous use do not offer the advantage of a diminished
effect on the coagulation system. Third, a recent ran-
domized trial of intracoronary SK versus direct coro-
nary angioplasty demonstrate clear-cut advantages
of mechanical therapy, once coronary access has
been obtained, with regard to ventricular function
and alleviation of the residual stenosis.26 Also, sev-
eral randomized trials of intracoronary versus intra-
venous SK underscore the advantage of simple,
rapid initiation of therapy.27-3’ Finally, although the
recanalization efficacy of intracoronary SK is rela-
tively high (approximately 75%), newer, intrave-
nously administered clot-selective agents such as
tissue-plasminogen activator (t-PA) have achieved
similar patency rates.3234 For all these considera-
tions, future use of thrombolytic therapy for myo-
cardial infarction will be by the intravenous rather
than the intracoronary route.
MODERN TRIALS OF INTRAVENOUS
STREPTOKINASE
In Table I, the major randomized trials of intrave-
nous SK are summarized. All of these trials have
used a 1.5 million unit SK dose given intravenously
over 30 to 60 minutes. The two megatrials, GISSI and
ISIS-2, collectively account for more than 30,000
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Dose (%) % (% Baseline)
Collen et al.32 1984 DC 42 0.5-0.75 mg/kg 72 9 92
Williams et al.33 1985 DC 47 80 mg/3 hr 68 32 71
TIM! (phase I) 1985 DC 143 80 mg/3 hr 66 6-10 67
Verstraete et al.45 1985 DC 64 0.75 mg/kg 70 8 76
Verstraete et al. 1985 DC 64 0.75 mg/kg x 1.5 hr 61 2 52
Gold et al.43 1985 DC 29 0.4-0.75 mg/kg X 1-2 hr 83 NR 62
Topoi et al. 1987 SC 100 1.25 mg/kg X 3 hr 84 23 65
Topol et al.48 1987 SC 386 1.0 mg/kg X 1 hr then 15 75 32 47
mg/hr X 5 hr (total = 150)
TIMI (phase IE)49 1986 SC 258 90 mg/first hr. 60 mg over 4 85* NR NR
hr
* Angiography at 18-48 hr.
DC = double chain; NR = not reported; SC single
Modified with permission from Collen and Topol:
activator, in Topol EJ (ed): Acute coronary Intervention. New York, Alan R. Liss,
chain. 1987.
Tissue-type plasminogen
randomized patients and demonstrate a 20% and
33% reduction in mortality, respectively.35-36 Only
the preliminary results of the placebo-controlled
ISIS-2 trial are available thus far. The series con-
sisted of approximately 4000 patients treated within
4 hours of symptom onset. Smaller trials that have
also demonstrated salutary effects of IV SK include
ISAM, the Western Washington, and the New Zea-
land studies. The ISAM trial sample size of 1741 pa-
tients was inadequate to detect an effect on mortal-
ity, but ventricular function was improved in the
subset of patients (55% of total) who underwent ven-
tricular function study. Also, CK-isoenzyme analysis
showed a reduction of infarct size for the patients
treated with SK compared with placebo.37 The West-
ern Washington trial of 368 patients did not demon-
strate significant overall mortality or ventricular
function benefit, but subgroup analysis demon-
strated that patients with anterior infarction or those
receiving SK within 3 hours derived significant re-
covery of ventricular function.38 In contrast, the
smaller New Zealand trial demonstrated significant
overall beneficial ventricular function and in-
creased survival effects.39
These five controlled studies of streptokinase did
not incorporate early coronary angiography, so that
the direct measure of efficacy-acute infarct vessel
recanalization-was not detected. Of course, most of
these studies would not have been possible if they
required emergency coronary angiography. Other
studies in which pretreatment or posttreatment an-
giography, or both, were performed demonstrated a
relatively low, 50% efficacy for this agent given in-
travenously.15-40-42 This discrepancy between rela-
tively low recanalization efficacy and favorable
clinical outcomes has led to the question of the ac-
tual mechanism of SK. This is discussed in
“Nonthrombolytic and Rheologic Effects” and “Reg-
ulatory Issues.”
CLINICAL TRIALS OF TISSUE
PLASMINOGEN ACTIVATOR
In contrast to the intravenous SK studies cited
above, the experience with t-PA is considerably less
in patient numbers but far greater with respect to
angiographic characterization. In Table II, the pub-
lished trials of IV t-PA are summarized. A two-chain
preparation of t-PA (Genentech, San Francisco, CA)
was used when the first patient received recombi-
nant t-PA in February 1984. By late 1985, six clinical
trials had been completed32’33’43-46 with this prepara-
tion, and upscaling required a new production
method (suspension culture), yielding a predomi-
nantly single-chain preparation. The dosing of t-PA
is highly dependent on the preparation method, be-
cause the single-chain preparation has a 40% more
rapid clearance.34 The difference in pharmacoki-
netics is not actually related to the two-versus 1-
chain characteristic but rather to other characteris-
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tics of the production process.47 All clinical trials
performed since late 1985 have used the suspen-
sion-culture preparation.34’485’
Several important results emerged from these
t-PA trials. First, the remarkably high and consistent
level of infarct vessel patency achieved of 70 to 75%
has been demonstrated with IV t-PA even though
the dose and preparation method varied. Second,
initial studies suggested that reocclusion may be
more problematic with t-PA,33’43 but the use of a
maintenance infusion (duration of therapy after the
first-hour dose) for 3 to 6 hours reduced the rate of
reocclusion to less than 12%.4348 The short half-life
of the agent (<5 mm) is particularly advantageous in
the clinical setting of acute myocardial infarction.
Once thrombolytic therapy has been initiated, the
need may arise for emergency coronary bypass sur-
gery or central venous access for temporary ventric-
ular pacing. If significant pen-access or other bleed-
ing occurs, the t-PA infusion can be stopped. Third,
some fibrinogen and plasminogen breakdown
clearly occurs with t-PA in such a way that this
agent has relative but not absolute fibrin selectiv-
ity.52-54 With the current dosing regimens, the fi-
brinogen nadir is approximately 30 to 50% of the
baseline value, with only 10 to 12% exhibiting
values of fibrinogen below 100 mg/dL.5355 Fourth,
using pretreatment angiography, the Thrombolysis
in Myocardial Infarction (TIMI) investigators dem-
onstrated that a higher dose in the first hour does not
increase the 90-minute patency rate but that it
clearly speeds up the recanalization process.51’55
OTHER THROMBOLYTIC AGENTS:
UROKINASE, APSAC, PROUROKINASE
Experience with IV urokinase to date has been rela-
tively limited although Mathey demonstrated a 60%
patency rate in a consecutive group of 50 patients,56
and there are ongoing randomized comparative
trials with t-PA and streptokinase. Cumulatively,
more than 1000 patients have been treated with ac-
ylated streptokinase (APSAC),5763 but a recent mul-
ticenter randomized-comparative trial with pre-
treatment angiography demonstrated only a 44% re-
canalization frequency with APSAC 30 mg IV.57
Both urokinase and APSAC can be given as a bolus
and result in marked fibrinogen breakdown quite
similar to that observed with SK. Like SK, APSAC is
antigenic and, thus, will provoke a low incidence of
allergic reactions(<5%) and has limited use for re-
peat dosing. Urokinase is a direct plasminogen acti-
vator without antigenicity or resistance. Prouroki-
nase (scu-PA) is a naturally occurring human en-
zyme and is the single-chain precursor. To date,
there is limited published experience with scu-PA,
and no large trials have been completed. The small
clinical experience suggests that scu-PA has an ade-
quate (>50-60%) infarct vessel patency rate and the
agent has a short half-life akin to t-PA.’65
STREPTOKINASE VERSUS TISSUE
PLASMINOGEN ACTIVATOR
To prevent the need for speculation, there have been
two multicenter, randomized trials of IV SK com-
pared with t-PA.45’46 The results of these trials and
related comparative information are shown in Table
III. The TIMI phase I trial was devoted to establish-
ing which of the two agents was better. Using a dou-
ble-blind randomization, the TIMI Study Group
showed there was a marked improvement of reper-
fusion rate with t-PA compared with SK. At seven
serial observations during the first 90 minutes after
onset of treatment, t-PA resulted in twice the reper-
fusion rate (90 minutes: 62% vs 31%, P < .001). The
striking difference in efficacy is demonstrated in
Figure 1 for either infarct vessels with TIMI grade 0
(no perfusion) or those with TIMI grade I (penetra-
tion without perfusion). These unanticipated, ex-
treme differences in reperfusion frequency between
the two agents resulted in premature termination of
the trial.46
This trial has been criticized for a number of rea-
sons.66’67 First, the patients were treated relatively
late, at 4.8 hours, related to the requirement for pre-
treatment angiography. In retrospect, it became
clear that SK was highly time dependent for achiev-
ing efficacy, so that administration more than 3 to 4
hours from the onset of symptoms resulted in ex-
tremely poor thrombolytic efficacy, approaching
that seen with spontaneous recanalization.6’4’ In Fig-
ure 2, the results from TIMI graphically show time
dependency of SK and lack of this characteristic for
t-PA. However, superior thrombolytic efficacy was
evident for t-PA versus SK even when the agents
were administered fewer than 4 hours from symp-
tom onset. Although a minority of patients (101 of
290, or 35%) treated in this trial were less than 4
hours from symptom onset, data from the European
Cooperative trial, in which patients received t-PA at
2.6 hours from symptom onset (no pretreatment an-
giography), also demonstrated superior t-PA versus
SK efficacy (70 vs 55%, respectively, P = .054) (Fig-
ure 3). Thus, t-PA has been unequivocally demon-
strated to have improved thrombolytic efficacy over
SK in two randomized trials over a broad time span
(Figure 4). These findings account for the selection of
t-PA as the agent of choice for future large-scale
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* Projected cost, not FDA approved at time of report.
trials in both the United States (TIMI) and Eu#{231}opean
Cooperative Study groups.
Second, it has been argued that the dose of SK
selected led to inherent bias.66’67 The standard mod-
ern dose of 1.5 million units of SK was given in both
trials, and all published experience with SK does not
show a relationship between dose and recanaliza-
tion rate.28’29-4042’68 Third, there was significant
(33%) t-PA-induced fibrmnogenolysis in TIMI, al-
though nearly half that which was observed with
SK.69 Despite relative sparing of coagulation pro-
teins, t-PA did not result in a reduction of bleeding
complications in TIMI, which chiefly involved pen-
access sites. Although the European Cooperative
Study demonstrated less bleeding episodes or trans-
fusion requirements for t-PA than SK,45 the overall
clinical trial bleeding complication rates with t-PA
have not been significantly decreased compared
with other lytic agents.
The reasons for this observation are multiple. A
potent fibrinolytic enzyme, t-PA will lead to lysis of
hemostatic plugs and noncoronary fibrin. Cardiac
catheterization performed in the face of lytic ther-
apy promotes the frequency and severity of pen-ac-
cess hemorrhage. Adj unctive thromboprophylactic
therapy with IV-administered heparin and anti-
platelet agents further increases the likelihood of
bleeding episodes.
Intracranial hemorrhage is the most serious and
often catastrophic complication of fibninolytic ther-
apy. With IV-administered t-PA at a total dose of 150
mg, an increased incidence of 1.6% (approximately
16 of 1000 patients) was observed.49’50’72 At doses up
to 120 mg, however, the rate has been 0.4%. Intra-
cranial bleeding appears to have a similarly low in-
cidence with high-dose IV SK, with most reports cit-
ing less than %,35.37.38 However, little is known
about the pathophysiology of cerebrovascular
bleeding induced by fibrmnolytic therapy. The demo-
graphic risk factors that have thus far been asso-
ciated with this event include female gender, ad-
vanced age, and long-standing or severe hyperten-
sion.48 More data and understanding will be
necessary before this dreaded complication can be
avoided with any of the fibrinolytic enzymes.
Besides bleeding complications, the major con-
cern after successful thrombolysis is for sustained
patency of the infarct vessel. Because serial acute
and follow-up angiography has not been performed
in any large-scale trial with IV SK, the true inci-
dence of reocclusion is completely unknown.
Smaller studies of IV SK have reported a wide range
of reocciusion from 5 to 30%.40424546 The TAMI trial
defined the angiographic reocclusion rate with t-PA
with the use of acute coronary angiography in 386
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Figure 1. Coronary thron,bolyfic efficacy of tissue plasminogen activator (1-PA) versus streptokinase (SK). At seven serial time intervals of
angiographic observation up to 90 minutes after the start of therapy, I-PA elicited reperfusion twice as often. (Reprinted with permission.
Cheseboro et alt Circulation 1987:76:142-154,)
patients. For those patients with a significant resid-
ual stenosis who did not undergo angioplasty, the
incidence of reocclusion was 13% (total t-PA dose
= 150 mg/6-8 hr).48
LEFT VENTRICULAR FUNCTION
AND MORTALITY
Two recent randomized, double-blind, placebo-con-
trolled trials of t-PA have demonstrated significant
left ventricular improvement. Both the Johns Hop-
kins and Australian trials were just completed, but
preliminary data are quite similar and support a
seven- to eight-point global ejection-fraction advan-
tage for patients receiving t-PA compared with pla-
cebo.70-72 There has not yet been a large enough ran-
domized, prospective trial of t-PA compared with
placebo or other reperfusion strategies to evaluate
mortality effects.
The placebo-controlled IV SK studies that have
addressed left ventricular function are those of
ISAM, Western Washington and New Zealand.37-39
In ISAM, only a subset of patients were studied, but
patients receiving SK had an increased global ejec-
tion fraction. Subgroup analysis of the Western
Washington trial demonstrated improvement of left
ventricular function in patients with anterior in-
farction. Despite the relatively small size of the New
Zealand trial, mortality was reduced and global
ejection fraction was increased in the SK-treated pa-
tients. As discussed earlier, the GISSI and ISIS-2
megatnials convincingly demonstrated the survival
advantage conferred by early administration of SK




Recently, the U.S. FDA Candiorenal Advisory Com-
mittee pointed out the disproportionate effects of IV
SK on infarct vessel recanalization compared with
mortality reduction.72 With SK thrombolytic efficacy
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Figure 2. Difference of lytic efficacy of tissue plasminogen activator (t-PA) versus streptokinase (SK) over time. No significant difference was
noted for patients treated less than or more than 4 hours from symptom onset with t-PA compared with substantially less efficacy for Sl(
after 4 hours. (Reprinted with permission. Cheseboro et at: Circulation 1987:76:142-154.
substantial reduction of 20 to 33%15.35.:36 the com-
mittee members suggested that the nonthrombolytic
actions of IV SK may be operational. Of the various
actions of SK, blood pressure reduction, viscosity re-
duction, and attendant rheologic alterations, anti-
platelet effects, and free oxygen radical scavenging
properties are potentially beneficial in the setting of
myocardial reperfusion. However, none of these
properties has been adequately evaluated in pro-
spective, clinical trials.
By report of the manufacturers, systolic blood
pressure reduction with IV SK is modest, averaging
only 5 to 7 mm Hg.72 Clearly, this minimal diminu-
tion of blood pressure would not be associated with a
significant afterload reduction. Furthermore, acute-
phase reduction of blood pressure in myocardial in-
farction has not been demonstrated to limit infarct
size or decrease mortality in patients.73
Blood viscosity reduction with SK also appears to
be mild, averaging 10 to 17% in two reported stud-
ies.74-75 In a small comparative study, IV SK resulted
in a significant (60%) fibninogen reduction and only
a 10% decline in blood viscosity, whereas t-PA low-
Figure 3. Difference of infarct vessel patency for tissue plasmino-
gen activator (1-PA) versus streptokinase (SKI at 90 minutes of
therapy in the randomized European Cooperative Study. Patients
received SK at a median of 2.6 hours from symptom onset, (Re-
printed with permission. Erbel R: The European Cooperative Trials
in Acute Myocardial Infarction, in, Topol El (ed): Acute Coronary
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Figure 4. Consistent efficacy of tissue plasminogen activator (t-PA)
over a broad time window. In a total of 1073 patients treated with
IV t-PA between 20 minutes and 8 hours from symptom onset, a
high level of infarct vessel patency at 90 minutes was achieved,
(Data presented at FDA Cardiorenal Advisory Committee, May 29,
1987, Bethesda. MD, On file, Genentech, Inc., San Francisco, CA),
ered plasma fibrinogen by 20% and blood viscosity
by 6%. Red blood cell deformity was not differently
affected by SK versus t-PA.75 Although reduction in
viscosity is correlated with improved microcircula-
tory blood flow and decline in total peripheral resis-
tance,74-76 the modest changes of blood or plasma
viscosity demonstrated with SK may not be substan-
tial enough to significantly alter clinical outcome.
With scant data currently available, the viscosity
and rheologic effects of fibrinolytic agents certainly
require further investigation.
In an in vitro study comparing antiplatelet effects
of SK urokinase, and t-PA, the most substantial in-
hibitory action was demonstrated for t-PA, related to
platelet-fibnin binding.77 With higher levels of II-
brinogen degradation products (FDP) generated by
SK compared with t-PA, it is also possible that there
may be more disaggregation with the former agent.78
The actual platelet function in vivo effects in
humans for the various fibninolytic agents have not
been adequately differentiated to date.
The free oxygen radical scavenging property of SK
has been characterized as modest,79 and the impor-
tance of this effect in myocardial reperfusion is a
controversial subject.80’81 Limitation of reperfusion
injury by free radical scavengers has not been dem-
onstrated in humans although this is the focus of
current clinical trials.82 With SK weak scavenging
effect, it is unlikely to be of clinical significance.
Recently, t-PA was suggested to have a direct myo-
cardial function salutary effect in the experimental
feline model,83’84 but again no clinical data exists to
confirm or rebut this observation.
In summary, there are multiple modest non-
thrombolytic effects of SK, which have not been well
characterized. Moreover, none of the effects have
been correlated with favorable clinical outcome or
improvement in ventricular function.
REGULATORY ISSUES
The FDA advisory panel decision to recommend ap-
provability status for IV SK but not t-PA led to con-
siderable controversy.72-8589 As the data for the two
agents were carefully scrutinized, it became appar-
ent that the strengths and weakness for each were
diametrically opposed. On the one hand, little data
were available for the recanalization efficacy of IV
SK but the GISSI, ISIS-2 megatnials and pooled analy-
ses confirmed mortality reduction with this
agent.35-36’9#{176}For t-PA, considerable evidence for high
thrombolytic efficacy was presented, but lacking
was a lange-scale placebo-controlled trial for mortal-
ity effects. For both agents, data on improvement of
left ventricular function was presented but not ac-
cepted as conclusive for the panel. Also, there was
discussion regarding the different doses of t-PA used
in the trials (ranging from 90-150 mg total IV dose of
the single-chain preparation) and a completely inac-
curate account of the incidence of intracranial
bleeding.72 The latter unfortunately casted doubt
and concern over t-PA as a safe fibninolytic agent.
Since this meeting, data from two placebo-con-
trolled studies of t-PA which substantially show left
ventricular functional recovery, have become avail-
able.70’7’ The availability of these data to the FDA
may ultimately lead to approval of t-PA in upcoming
months. However, an important issue has been
raised by the panel’s decision. Should a fibninolytic
agent require proven mortality or ventricular func-
tion benefit before it can be approved for use in
myocardial infarction?
In 1982, when the FDA approved intracoronary
SK, the answer was clearly no. No data were avail-
able to confer more than coronary thrombolytic ef-
ficacy for this reperfusion strategy. Has the field so
changed in 5 years? Is coronary thrombolysis disso-
ciated from clinical outcomes and ventricular func-
tion?
From clinical experience and the data currently
available, it is clear that the major effect of all fibni-
nolytic agents in this setting is to lyse intraluminal
thrombus and restore blood flow through the af-
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fected coronary artery. Recanalization may be of
“cosmetic” benefit only when therapy is instituted
too late or when myonecrosis is already complete.
As long as fibrinolytic therapy is administered early
and judiciously, there will be definite overall im-
provement in ventricular function and reduction in
mortality. Denial of this principle violates the fun-
damental pathophysiology of acute myocardial in-
farction. Provided that safety of a fibrinolytic agent
is confirmed, correction of the underlying occlusive
clot disorder by lysis must be a desirable end point in
the patient with myocardium at jeopardy. The di-
lemma for future regulatory boards will be in the
definition of efficacy of a fibrinolytic agent. In a rap-
idly proliferating field of many new agents and man-
ufacturers, this will undoubtedly lead to difficulties.
If the effects of one fibrinolytic agent have correla-
tion between thrombolytic and clinical efficacy, will
this be adequate for all future enzymes? This ques-
tion is currently unsettled. The efficacy threshold
may be debated for many classes of drugs. For exam-
ple, should all hypertensive agents document sur-
vival and stroke-avoidance benefit beyond effective
lowering of blood pressure? Obviously, this is not
the case. However, the analogy to fibrinolytic ther-
apy is apparent.
FUTURE OF THROMBOLYTIC THERAPY
The last 5 years may be considered the rapid growth
phase of understanding and experience with throm-
bolytic therapy for acute myocardial infarction.
Concurrently, three new agents (t-PA, APSAC,
prourokinase) have been developed for clinical use,
and further biochemical modifications of these
agents and combination therapies are being ex-
plored.91-95 The ultimate goals of rapid, 100% coro-
nary thrombolytic efficacy, zero reocclusion, and
absence of bleeding are highly unlikely to be
achieved. There is no doubt, however, that consider-
able investigation will follow to approximate more
closely these important objectives. In planning fu-
ture clinical trials and eventual clinical release of
fibninolytic agents, regulatory agencies will have to
develop rational and consistent guidelines for the
definition of efficacy.
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